Forum Pharmaceuticals' lead compound encenicline has failed to meet the endpoints in two Phase III trials for the treatment of cognitive impairment in schizophrenia patients. .
While Forum – which is developing the product in partnership with Mitsubishi Tanabe Pharma –plans to analyze the data from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?